Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Opioid companies say lawyers' fee demand threatens settlement talks

Published 02/27/2020, 03:19 PM
© Reuters. FILE PHOTO: The logo of Teva Pharmaceutical Industries is seen during a news conference in Tel Aviv, Israel
TEVA
-
MCK
-
JNJ
-
TEVA
-

By Tom Hals and Nate Raymond

(Reuters) - Johnson & Johnson (N:JNJ) and other drug companies facing thousands of lawsuits over their role in the opioid epidemic have warned that settlement talks will be "severely" jeopardized if plaintiffs' lawyers are allowed to assess a fee payment worth billions of dollars.

Major distributors such as McKesson Corp (N:MCK) and drugmakers including Teva Pharmaceutical (NYSE:TEVA) Industries Ltd (TA:TEVA) joined in the request that U.S. District Judge Dan Polster in Cleveland, Ohio, reject a request by a committee of plaintiffs' lawyers for a 7% fee assessed against any settlements. They filed their brief late Wednesday.

The request could amount to $3.3 billion, based on a $48 billion settlement proposal that five companies have been negotiating with various state attorneys general.

The drug companies noted that the attorneys would receive more money from the settlement than even some of the states they represent. Dozens of state attorneys general also opposed the request for the fee to the plaintiffs executive committee that is litigating thousands of lawsuits by towns, counties and tribal governments.

The lawsuits, consolidated before Polster, accuse the companies of fueling a nationwide opioid crisis blamed for 400,000 U.S. overdose deaths since 1999.

Many local governments hired private attorneys and will have to carve out of any money received for a separate legal fee, which in some cases will be paid to the same attorneys who sit on the plaintiffs executive committee, or PEC.

"The scope of that demand is staggering," the companies said in Wednesday's joint filing. They said the 7% assessment would "give the PEC more money than any city or county in the country, and more than many states."

The PEC said members were engaged in negotiating a full and fair settlement with distributors and working to reach a broader settlement with opioid defendants.

"Common benefit fees are not a roadblock to resolution," the PEC said in a statement.

In court filings, PEC lawyers described the fee request as "modest" given the complex litigation. Such a fee, to compensate for lawyers' time and expenses, is a feature of complex nationwide litigation.

The fee request has also met opposition from state attorneys general, who brought their own opioid cases that are not before Polster.

In a letter to Polster on Monday, attorneys general from 36 states said plaintiffs' lawyers were wrongly seeking to tax any settlements the states achieve and that the fee request if approved could "irreparably" disrupt global settlement talks.

"Everyone understands these attorneys have done a lot of work," New Hampshire Associate Attorney General James Boffetti said. "But it doesn't mean they get a disproportionate windfall."

© Reuters. FILE PHOTO: The logo of Teva Pharmaceutical Industries is seen during a news conference in Tel Aviv, Israel

The parties are under pressure to resolve the lawsuits before the start of a March 20 trial in New York.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.